Back-





                                                        GlyConMedics


GlyConMedics LLC © 2018                                                   Privacy Policy                                                        info@glyconmedics.com
News
2018

Phase 2a Clinical Trial Approved in India (6th April 2018)
Patient recruitment is anticipated by 15th June 2018.

CEO Invited to Speak at The Microbiome R&D and Business
Collaboration Congress: Asia
(6th March 2018)
Presented latest insight into our technology at the conference.

Our patent granted in Russia (25th January 2018)
Russian Patent Office has granted our second patent.

2017

Our patent granted in China (17th December 2017)
China Patent Office has granted our second patent.

Our patent granted in Canada (30th October 2017)
Canadian Patent Office has granted our first patent.

CEO Invited as a keynote speaker at The International Diabetes
and Degenerative Diseases Conference
(18th September 2017)
Discussed the latest insight into our technology.

Our patent granted in USA (17th November 2017)
US Patent Office has granted our second patent.

Certificate of Special Congressional Recognition (01 February 2017)
52nd District, California

2016
Most Innovative New Product Finalist (6th October 2016)
Our technology has been elected as a finalist at the
2016 Most Innovative New Product Award, administered by CONNECT in San Diego, CA.

Microbiome R&D and Business Collaboration Forum (3-4 October 2016)
GlyConMedics CEO attended the 4th Microbiome Congress held in San Diego, CA.

Diabetes Innovation Challenge Semi-Finalist (16th August 2016)
Our technology has been elected as a semi-finalist at the Diabetes Innovation Challenge contest, administered by T1D Exchange and M2D2 Clinical, held at
University of Massachusetts, Boston.

Our first patent granted in China(16th March 2016)
Chinese Patent Office has granted our first patent.

Our first patent granted in USA (26th January 2016)
United States Patent and Trademark Office has granted our first patent.

Australia USA Business Week (16th - 26th Feb February 2016)
GlyConMedics CEO attended the inaugural Australia United State Business Week (AUSBW) that was held in six key cities across the United States – Boston,
Chicago, Houston, Los Angeles, New York and San Francisco.

2015
23rd World Diabetes Congress (30th November - 04 December 2015)
GlyConMedics CEO attended world diabetes congress organized by the International Diabetes Federation held at Vancouver, British Columbia, Canada.

Clinical Trial Conduct (14th October 2015)
Company phase 2 clinical trial has been approved by a Human Research Ethics Committee in India.

2014
Clinical Trial Conduct (4th December 2014)
Company phase 2 clinical trial has been approved by a Human Research Ethics Committee in Australia.

First Patent granted (27th  October 2014)
IP Australia has granted our first patent.

Advisory and scientific Board (1st September 2014)
Professor Lesley Campbell has joined our scientific advisory board.

Advisory and scientific Board (28h August 2014)
Dr Ivan Rajkovic has joined our scientific advisory board.

Phase 2 Clinical Trials (16th June 2014)
We have initiated activities related to conduct of our proof of concept clinical trial.

Investment (4th June 2014)
We have secured our first round of family and friends Investments.

Our second Patent has entered the national phase (23th  May 2014)
Second PCT patent (PCT/AU2012/001442) entitled “Improved Synergistic Anti-Diabetic Compositions”, entered national phase in major countries.

Advisory and scientific Board (20th  May 2014)
Professor Anthony Barnett has joined our scientific advisory board.

Commercialisation Australia Grant (12th May 2014)
We have received our proof-of-concept grant from The Australian Government to further develop its product and services.

Australia Week In China (4th  Apr 2014)
GlyConMedics CEO attends Australia Week in China 2014 Conference organized by AusTrade to initiate dialogues with Chinese entities.

2013
Advisory and scientific Board (7th  Dec 2013)
Professor C. Ronald Kahn Chief Academic Officer of Joslin Diabetes Center, Boston has joined our scientific advisory board.

OZ101 tablets (7th  December 2013)
We have manufactured our first GMP tablet OZ101 to conduct our proof-of-concept clinical trial in Australia and India.

Acceptance of First Patent (17th  June 2013)
First patent entitled “Anti-Diabetic Compositions and Methods” granted in Australia.
First patent entitled “Anti-Diabetic Compositions and Methods”, entered national phase in major countries.

GlyConMedics LLC Founded (8th Mar 2013)
GlyConMedics LLC has been founded by Dr Nick N Gorgani.